vs
CARRIAGE SERVICES INC（CSV）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是CARRIAGE SERVICES INC的1.7倍（$177.4M vs $105.5M），CARRIAGE SERVICES INC净利率更高（11.6% vs 1.6%，领先10.0%），CARRIAGE SERVICES INC同比增速更快（8.0% vs 5.0%），过去两年CARRIAGE SERVICES INC的营收复合增速更高（1.0% vs -0.2%）
怡和Cycle & Carriage有限公司是怡和集团在东南亚的投资控股公司，目前该集团持有其75%的股份，是怡和集团在东南亚区域开展资本布局与投资业务的核心平台。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
CSV vs PCRX — 直观对比
营收规模更大
PCRX
是对方的1.7倍
$105.5M
营收增速更快
CSV
高出3.0%
5.0%
净利率更高
CSV
高出10.0%
1.6%
两年增速更快
CSV
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $105.5M | $177.4M |
| 净利润 | $12.3M | $2.9M |
| 毛利率 | 34.8% | — |
| 营业利润率 | 23.3% | 3.9% |
| 净利率 | 11.6% | 1.6% |
| 营收同比 | 8.0% | 5.0% |
| 净利润同比 | 24.5% | — |
| 每股收益（稀释后） | $0.76 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSVPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $105.5M | $196.9M | ||
| Q3 25 | $102.7M | $179.5M | ||
| Q2 25 | $102.1M | $181.1M | ||
| Q1 25 | $107.1M | $168.9M | ||
| Q4 24 | $97.7M | $187.3M | ||
| Q3 24 | $100.7M | $168.6M | ||
| Q2 24 | $102.3M | $178.0M |
净利润CSVPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.3M | — | ||
| Q3 25 | $6.6M | $5.4M | ||
| Q2 25 | $11.7M | $-4.8M | ||
| Q1 25 | $20.9M | $4.8M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.9M | $-143.5M | ||
| Q2 24 | $6.3M | $18.9M |
毛利率CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | 34.8% | 79.5% | ||
| Q3 25 | 35.3% | 80.9% | ||
| Q2 25 | 35.2% | 77.4% | ||
| Q1 25 | 35.3% | 79.7% | ||
| Q4 24 | 34.4% | 78.7% | ||
| Q3 24 | 35.2% | 76.9% | ||
| Q2 24 | 36.2% | 75.1% |
营业利润率CSVPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 23.3% | 1.2% | ||
| Q3 25 | 17.0% | 3.5% | ||
| Q2 25 | 23.5% | 4.7% | ||
| Q1 25 | 29.5% | 1.2% | ||
| Q4 24 | 21.6% | 13.2% | ||
| Q3 24 | 22.7% | -82.8% | ||
| Q2 24 | 18.0% | 15.9% |
净利率CSVPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 11.6% | — | ||
| Q3 25 | 6.4% | 3.0% | ||
| Q2 25 | 11.5% | -2.7% | ||
| Q1 25 | 19.5% | 2.8% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 9.8% | -85.1% | ||
| Q2 24 | 6.1% | 10.6% |
每股收益（稀释后）CSVPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.76 | $0.05 | ||
| Q3 25 | $0.41 | $0.12 | ||
| Q2 25 | $0.74 | $-0.11 | ||
| Q1 25 | $1.34 | $0.10 | ||
| Q4 24 | $0.62 | $0.38 | ||
| Q3 24 | $0.63 | $-3.11 | ||
| Q2 24 | $0.40 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $254.8M | $653.9M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSVPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.7M | $238.4M | ||
| Q3 25 | $1.2M | $246.3M | ||
| Q2 25 | $1.4M | $445.9M | ||
| Q1 25 | $4.6M | $493.6M | ||
| Q4 24 | $1.2M | $484.6M | ||
| Q3 24 | $1.3M | $453.8M | ||
| Q2 24 | $1.5M | $404.2M |
总债务CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CSVPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $254.8M | $693.1M | ||
| Q3 25 | $242.1M | $727.2M | ||
| Q2 25 | $235.4M | $757.8M | ||
| Q1 25 | $223.1M | $798.5M | ||
| Q4 24 | $208.6M | $778.3M | ||
| Q3 24 | $198.1M | $749.6M | ||
| Q2 24 | $187.9M | $879.3M |
总资产CSVPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B |
负债/权益比CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.1M | — |
| 自由现金流经营现金流 - 资本支出 | $6.2M | — |
| 自由现金流率自由现金流/营收 | 5.9% | — |
| 资本支出强度资本支出/营收 | 7.5% | — |
| 现金转化率经营现金流/净利润 | 1.15× | — |
| 过去12个月自由现金流最近4个季度 | $40.1M | — |
8季度趋势，按日历期对齐
经营现金流CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | $14.1M | $43.7M | ||
| Q3 25 | $24.7M | $60.8M | ||
| Q2 25 | $8.1M | $12.0M | ||
| Q1 25 | $13.8M | $35.5M | ||
| Q4 24 | $9.3M | $33.1M | ||
| Q3 24 | $20.9M | $53.9M | ||
| Q2 24 | $2.2M | $53.2M |
自由现金流CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | $6.2M | $43.5M | ||
| Q3 25 | $18.0M | $57.0M | ||
| Q2 25 | $5.2M | $9.3M | ||
| Q1 25 | $10.6M | $26.9M | ||
| Q4 24 | $4.9M | $31.0M | ||
| Q3 24 | $16.2M | $49.8M | ||
| Q2 24 | $-1.4M | $51.6M |
自由现金流率CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 22.1% | ||
| Q3 25 | 17.5% | 31.7% | ||
| Q2 25 | 5.1% | 5.1% | ||
| Q1 25 | 9.9% | 15.9% | ||
| Q4 24 | 5.0% | 16.6% | ||
| Q3 24 | 16.1% | 29.6% | ||
| Q2 24 | -1.4% | 29.0% |
资本支出强度CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | 7.5% | 0.1% | ||
| Q3 25 | 6.5% | 2.2% | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 3.0% | 5.1% | ||
| Q4 24 | 4.5% | 1.1% | ||
| Q3 24 | 4.6% | 2.4% | ||
| Q2 24 | 3.5% | 0.9% |
现金转化率CSVPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.15× | — | ||
| Q3 25 | 3.76× | 11.20× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.66× | 7.37× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 0.34× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
